Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02090998 · ClinicalTrials.gov registry record · Phase 4
Sphenopalatine Ganglion Nerve Block vs. Elavil for Treatment of Transformed Migraines
A Phase 4 study, sponsored by Rutgers, The State University of New Jersey.
- Terminated
- Registry status
- Phase 4
- Development phase
- 10
- Enrollment target
NCT02090998 is a Phase 4 study that was terminated before completion, run by Rutgers, The State University of New Jersey. The registered enrollment target is 10 participants.
The verdict
NCT02090998, a Phase 4 study, was terminated before completion, sponsored by Rutgers, The State University of New Jersey.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 10 participants
- Enrollment target
Study Summary
This study will compare a local anesthetic technique that has been used to treat subjects suffering from transformed migraines (chronic migraines) versus medical management with traditional antidepressant Amitriptyline / Elavil. Subjects will be randomized into one of two treatment groups to compare the safety and efficacy of the therapies. Subjects will recieve either sphenopalatine ganglion nerve block with 5% lidocaine gel into the nasopharynx or medical management with traditional antidepressants, Elavil, to produce a reduction in the frequency and severity of the headache. We propose that there will be a difference in the outcomes when comparing the two methods of treating transformed migraines and that one research arm will result in more patient satisfaction and greater efficacy in the treatment of subjects
Interventions
- DRUG Amitriptyline
- PROCEDURE SPG Block with 5% Lidocaine gel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2014-05 |
| Est. Completion | 2020-03-16 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02090998
The ClinicalTrials.gov registry entry for NCT02090998 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rutgers, The State University of New Jersey, which has 413 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Amitriptyline is the first listed.
NCT02090998 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02090998 about?
NCT02090998 is a clinical study titled "Sphenopalatine Ganglion Nerve Block vs. Elavil for Treatment of Transformed Migraines". This study will compare a local anesthetic technique that has been used to treat subjects suffering from transformed migraines (chronic migraines) versus medical management with traditional antidepressant Amitriptyline / Elavil. Subjects will be randomized into one of two treatment groups to compar...
What is the current status of trial NCT02090998?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 10 participants. The study started on 2014-05. Estimated completion is 2020-03-16.
What interventions are being tested in trial NCT02090998?
The interventions under investigation include: Amitriptyline (DRUG), SPG Block with 5% Lidocaine gel (PROCEDURE).
Who is sponsoring clinical trial NCT02090998?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.